Deep vein thrombosis is a blood clot that forms in a deep vein, usually in the leg. It affects about 900,000 people in the U.S. each year. Treatment typically involves anticoagulants (blood thinners) to prevent the clot from growing and reduce the risk of pulmonary embolism, a potentially life-threatening complication.
What's actually going on in research
Trials are testing direct oral anticoagulants (DOACs) like apixaban and rivaroxaban in different populations, shorter treatment durations to minimize bleeding risk, devices that remove clots directly, and better ways to predict who needs extended anticoagulation. Researchers are also studying prevention strategies for high-risk groups including cancer patients and people after surgery.
Clot removal devices
Catheter-based devices can physically remove clots from large veins in the leg. Trials are comparing these devices to standard anticoagulation alone to see if they prevent post-thrombotic syndrome, the chronic leg pain and swelling that affects many DVT patients.
Shorter treatment courses
Studies are testing whether some patients can safely stop anticoagulation after three months instead of extended treatment. The goal is to prevent bleeding complications while still protecting against recurrent clots.
Cancer-associated clots
Cancer patients face high DVT risk and complications from both clots and anticoagulation. Trials are testing which blood thinners work best in this population and how long treatment should continue.
What to know before you search
Eligibility typically depends on whether the DVT is a first episode or recurrent, location of the clot, presence of cancer or other medical conditions, and recent bleeding history.
What types of trials are currently open
- Anticoagulation trials — Testing different blood thinners, doses, or treatment durations to find the best balance between preventing clots and minimizing bleeding risk.
- Device trials — Testing catheter-based devices that physically remove clots to see if they prevent long-term leg problems better than medication alone.
- Prevention trials — Testing strategies to prevent DVT in high-risk groups like surgical patients, cancer patients, or people with clotting disorders.
- Post-thrombotic syndrome trials — Testing treatments for the chronic leg pain, swelling, and skin changes that can develop after DVT.
- Diagnostic studies — Testing blood tests or imaging techniques to better identify who has DVT or who is at high risk for recurrence.
Recently added Deep Vein Thrombosis trials
Share your recovery data to help predict blood clot risk after leg injuries
This is a prospective, multicenter, observational cohort study designed to externally validate the Trauma-Related Immobilization-related Prophylaxis (TRiP(cast)) score in Tunisian adults with acute lower-limb trauma requiring immobilization and managed as outpatients. The study will assess the ability of the TRiP(cast) score to identify patients at increased risk of symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. A secondary objective is to evaluate adherence to prescribed thromboprophylaxis and to compare adherence between patients receiving low-molecular-weight heparin (LMWH) and those receiving direct oral anticoagulants (DOACs). Factors associated with treatment adherence, bleeding events, and thromboembolic outcomes will also be investigated. Patients aged 18 years or older with acute lower-limb trauma requiring immobilization for at least 7 days will be enrolled consecutively and followed prospectively. The decision to prescribe thromboprophylaxis and the choice of anticoagulant will remain entirely at the discretion of the treating physician according to routine clinical practice. Study investigators will not influence treatment decisions. The results are expected to provide external validation of the TRiP(cast) score in the Tunisian population and improve risk stratification and thromboprophylaxis management in ambulatory patients with lower-limb trauma.
Receive a stent in your leg vein to treat ulcers
Outcomes of iliac vein stenting with dedicated venous stents in treatment of chronic post-thrombotic venous ulcers Deep vein thrombosis (DVT) affects 1 to 3 individuals per 1000 annually. Among these patients, 20% to 50% may develop post-thrombotic syndrome (PTS), with the likelihood varying based on the extent and location of the thrombus. Notably, despite receiving anticoagulation therapy, 5% to 10% of patients may progress to severe PTS, potentially leading to the development of venous ulcers (Afsha Aurshina, 2018). Chronic venous obstruction (CVO) refers to the impediment of venous flow, typically resulting from either partial or complete blockage of the venous system. This obstruction leads to diminished venous flow and elevated pressure within the affected veins. CVO serves as a broad descriptor for various conditions, including post-thrombotic syndrome (PTS) and nonthrombotic iliac vein lesions (NIVLs). PTS commonly arises as a complication of deep vein thrombosis (DVT), with estimates indicating that up to 50% of patients diagnosed with iliofemoral DVT will develop PTS within two years following their initial diagnosis. (Mohammad E. Barbati, 2024) The study aims to know the outcomes of iliac vein stenting with dedicated venous stenting in the treatment of post-thrombotic syndrome venous ulcer. Type of Study: Prospective single arm cohort study * Study Setting: Ain Shams University hospitals * Study Period: 2 years with 6 months follow up * Sample Size: 20 patients. * Study Population Patients presenting to the outpatient clinic at Ain Shams University Hospitals with venous ulcers. * Study Tools * 20 patients will be selected. * Written informed consent. * Full history taking, personal history , risk factors of DVT, presence of any medical illness , assessment of QOL based on CVIQ 20 - questionnaire, list of symptoms, sensations or types of discomfort that you may or may not be experiencing and which may make everyday life hard to bear to a greater or lesser extent. * Clinical evaluation: based on revised Venous Clinical Severity Score rVCSS , Villalta score and CEAP classification . rVCSS includes 10 items, such as pain, varicose veins, oedema, skin pigmentation, inflammation, skin induration, number of active ulcers, ulcer size, duration of ulcer, and application of pressure therapy. Each item is scored from 0 to 3 according to the severity, and the total score is 30. A higher score indicates higher severity. And using villlata score It can be used to both diagnose and categories the severity of the condition. The Villalta score involves both the patient who grades the presence and severity (0-3 points) of five symptoms ( pain , cramps, heaviness, parasthesia and pruritus ) and and the physician who grades six clinical signs(Pre-tibial oedema, Hyper-pigmentation, Redness, Venous Ectasia, ain on calf compression, ulcers) (0-3 points) after examination of the lower limb. Also the clinical severity of the venous disease will be graded according to the clinical, etiological, anatomical, and pathophysiological (CEAP) scoring system, and assessment of venous ulcer assessment (by onset, course, duration, site, size, shape
Find Deep Vein Thrombosis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.